The landmark FOURIER and ODYSSEY OUTCOMES studies were critical to the PCSK9 field. Both provide definitive proof that PCSK9 inhibition, on top of statin, reduces cardiovascular events in very high-risk patients.

Consistent with the mission of PCSK9 Forum, a complementary series of slide resources for clinicians which capture the essentials of these trials will soon be available. These decks will provide a novel addition to the educational tools already available.

Bookmark PCSK9 Forum to check back for the first of these unique resources.